Case 31-2011: A 55-year-old man with oligometastatic lung cancer

New England Journal of Medicine

Volumn 365, Issue 15, 2011, Pages 1426-1435

  Lanuti, Michael ^a,b   Sequist, Lecia V ^a,b   Sharma, Amita ^a,b   Mino Kenudson, Mari ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; ERLOTINIB; FENOFIBRATE; GEFITINIB; PACLITAXEL; SERTRALINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ADULT; APPENDECTOMY; ARTICLE; ASPIRATION BIOPSY; BRAIN METASTASIS; BRAIN TUMOR; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTODIAGNOSIS; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG HYPERSENSITIVITY; DYSPNEA; FATIGUE; HEADACHE; HEMORRHOIDECTOMY; HERNIOPLASTY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; INGUINAL HERNIA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMETASTATIC LUNG CANCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; WALKING DIFFICULTY; WEAKNESS; BRAIN; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DRUG ANTAGONISM; GENETICS; LUNG; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROTO ONCOGENE; RADIOGRAPHY;

BRAIN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; GENES, ERBB-1; HUMANS; LUNG; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80054036171     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc1013930     Document Type: Article

References (32)

1. Detterbeck FC, Jones DR, Molina PL. Extrathoracic staging. In: Detterbeck FC, Socinski MA, Rivera MP, Rosenman JG, eds. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia: W.B. Saunders, 2001:94-110.
2. Knights EM Jr. Metastatic tumors of the brain and their relation to primary and secondary pulmonary cancer. Cancer 1954;7:259-65.
3. Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 2001;122:548-53. (Pubitemid 32843957)
4. Bonnette P, Puyo P, Gabriel C, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 2001;119:1469-75. (Pubitemid 32686031)
5. Burt M, Wronski M, Arbit E, Galicich JH. Resection of brain metastases from non-small-cell lung carcinoma: results of therapy. J Thorac Cardiovasc Surg 1992; 103:399-411.
6. Getman V, Devyatko E, Dunkler D, et al. Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment. Eur J Cardiothorac Surg 2004; 25:1107-13. (Pubitemid 38622356)
7. Mussi A, Pistolesi M, Lucchi M, et al. Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors. J Thorac Cardiovasc Surg 1996;112:146-53. (Pubitemid 26268981)
8. Rossi NP, Zavala DC, VanGilder JC. A combined surgical approach to non-oat-cell pulmonary carcinoma with single cerebral metastasis. Respiration 1987;51:170-8. (Pubitemid 17067485)
9. Magilligan DJ Jr, Duvernoy C, Malik G, Lewis JW Jr, Knighton R, Ausman JI. Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience. Ann Thorac Surg 1986;42:360-4. (Pubitemid 16033263)
10. Wroński M, Arbit E, Burt M, Galicich JH. Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg 1995; 83:605-16.
11. Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:17-32.
12. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:45-68. [Erratum, J Neurooncol 2010;96:69-70.]
13. Detterbeck FC, Jones DR, Kernstine KH, Naunheim KS. Lung cancer: special treatment issues. Chest 2003;123:Suppl:244S-258S. (Pubitemid 36135721)
14. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers"and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. (Pubitemid 39209661)
15. Sequist LV, Joshi VA, Janne PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007;12:90-8. (Pubitemid 46143506)
16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
17. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
18. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-95. (Pubitemid 350002967)
19. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
20. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as firstline therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95: 998-1004. (Pubitemid 44606825)
21. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6. (Pubitemid 46638887)
22. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9. [Erratum, J Clin Oncol 2008;26:3472.]
23. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non - small-cell lung cancer. N Engl J Med 2002;346:92-8. (Pubitemid 34438899)
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel - carboplatin alone or with bevacizumab for non - small-cell lung cancer. N Engl J Med 2006;355:2542-50. [Erratum, N Engl J Med 2007;356:318.] (Pubitemid 44917502)
25. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
26. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin - paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
27. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
28. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non - small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
29. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
30. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
31. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66.
32. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.